Evidence map›Paper›PMID 31226730›Full record

ArticleInternational journal of molecular sciences2019

Novel Selective Estrogen Receptor Modulator Ameliorates Murine Colitis.

Lauri Polari, Santeri Anttila, Terhi Helenius, Anu Wiklund, Tero Linnanen, Diana M Toivola, Jorma Määttä

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Loss of ERβ in Aging LXRαβ Knockout Mice Leads to Colitis.International journal of molecular sciences · 2023
    Article
  7. FermentedFrontiers in nutrition · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lauri PolariInstitute of Biomedicine, University of Turku, FI-20520 Turku, Finland. lauri.polari@utu.fi.ORCID 0000-0002-0052-6489
Santeri AnttilaInstitute of Biomedicine, University of Turku, FI-20520 Turku, Finland. sjmant@utu.fi.
Terhi HeleniusFaculty of Science and Engineering, Department Biosciences, Cell Biology; Åbo Akademi University, FI-20520 Turku, Finland. terhi.helenius@abo.fi.
Anu WiklundInstitute of Biomedicine, University of Turku, FI-20520 Turku, Finland. anu.wiklund@gmail.com.
Tero LinnanenForendo Pharma Ltd., FI-20520 Turku, Finland. tero.linnanen@forendo.com.
Diana M ToivolaFaculty of Science and Engineering, Department Biosciences, Cell Biology; Åbo Akademi University, FI-20520 Turku, Finland. diana.toivola@abo.fi.
Jorma MäättäInstitute of Biomedicine, University of Turku, FI-20520 Turku, Finland. jmaatta@utu.fi.
Åbo Akademi University · FIUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Estrogen-receptor-mediated signaling has been suggested to decrease the inflammatory response in monocyte macrophages. Previously, we showed that a novel selective estrogen receptor modulator (SERM2) promotes anti-inflammatory phenotype of monocytes in vitro. In this study, we demonstrate the potential of SERM2 in amelioration of colitis. We utilized a dextran sodium sulfate (DSS)-induced colitis model in FVB/n mice to demonstrate the effects of orally administered SERM2 on the clinical status of the mice and the histopathological changes in the colon, as well as proportion of Mrc-1 positive macrophages. SERM2 nuclear receptor affinities were measured by radioligand binding assays. Orally administered, this compound significantly alleviated DSS-induced colitis in male mice and induced local estrogen receptor activation in the inflamed colon, as well as promoting anti-inflammatory cytokine expression and infiltration of anti-inflammatory monocytes. We show that this novel drug candidate has an affinity to estrogen receptors α and β and progesterone receptors, but not to glucocorticoid receptor, thus expressing unique binding properties compared to other sex steroid receptor ligands. These results indicate that novel drug candidates to alleviate inflammatory conditions of the colon could be found among sex steroid receptor activating compounds.

Indexed as

AnimalsColitisColonCytokinesDextran SulfateDisease Models, AnimalMaleMiceMonocytesSelective Estrogen Receptor ModulatorsCytokinesDextran SulfateSelective Estrogen Receptor Modulatorscolitisestrogen receptorinflammationmacrophagesprogesterone receptorselective estrogen receptor modulator

Identifiers

PMID31226730
PMCPMC6627219
OpenAlexW2951220652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.